@article{oai:kanazawa-u.repo.nii.ac.jp:00013790,
 author = {絹谷, 清剛},
 issue = {2},
 journal = {癌と化学療法 = Cancer & chemotherapy},
 month = {Jan},
 note = {放射性医薬品による選択的病巣集積を利用した治療を，アイソトープ内用療法（内照射療法）という。甲状腺分化癌に対する放射性ヨウ素内用療法などの既存の内照射療法のニーズは徐々に高まりをみせ，現在，新規内用療法製剤の導入が図られている。本稿では，現在行われている内用療法の今後の方向性，現状の問題点・解決策などを概観する。 Treatment with radiopharmaceuticals which selectively target lesions is called targeted radionuclide therapy(TRT). These days, the requirement for TRTs such as treatment for differentiated thyroid cancer with radioactive iodine, is on the increase. In addition, a new TRT agent is currently in a clinical trial. Here, current issues regarding TRT and its possible future use are discussed.},
 pages = {133--138},
 title = {アイソトープ内用療法（内照射療法）の進むべき方向},
 volume = {40},
 year = {2013}
}